induced cell apoptosis and reduced the formation of SGs (Fig.1C) . We found anti-apoptotic gene cyclooxygenase 2 (cox2) was recruited into SGs. And the expression of cox2 was higher in sorafenib-resistant cells. RNA-based fluorescence in-situ hybridization (RNA-FISH) experiment was performed to observe the cellular distribution of cox2 mRNA. In sorafenib-treated cells, many particle-like distribution of cox2 mRNAs were found to be co-localized with SGs (Fig.2) . To override sorafenib resistance, we inactivated cox2 using celecoxib, a clinical analgesic specific cox2 inhibitor. A combination treatment with low dosage of celecoxib and sorafenib induces ACHN cells death more efficient than sorafenib alone (Fig.3) .
INTRODUCTION AND OBJECTIVES:
Molecularly targeted therapeutics, such as sunitinib, have been widely used for patients with advanced renal cell carcinoma (RCC). However, survival benefit from them is limited due to acquiring resistance. Recently, bromodomain family proteins such as BRD4, epigenetic regulator of acetylated histones in chromatin, have been identified as promising therapeutic targets, and its inhibitor JQ1 has shown inhibitory effects in several types of cancer. However, anti-cancer effects of JQ1 in RCC, especially sunitinib-resistant RCC is still unclear. In this study, we aimed to elucidate anti-cancer effects of BRD4 inhibition by JQ1, and the mechanism underlying BRD4 inhibition in sunitinib-sensitive and -resistant RCCs.
METHODS: BRD4 expressions in RCC cell lines including sunitinib-resistant 786-o cells (SU-R-786-o), which we previously established, were determined by qRT-PCR. By using JQ1, we performed cell proliferation assays, cell cycle assays and apoptosis assays in vitro, and xenograft assays. To elucidate molecular mechanisms regulated by BRD4, RNA sequence analysis was performed using JQ1 treated-or untreated-SU-R-786-o and parent 786-o cells. In addition, we performed statistical analyses based on The Cancer Genome Atlas (TCGA) database of RCC patients.
RESULTS: BRD4 expression was significantly upregulated in RCC cell lines compared to normal kidney (P < 0.05). In addition, SU-R-786-o showed elevation of BRD4 expression in comparison with parent 786-o (P ¼ 0.0014). TCGA database showed that high BRD4 expression associated with poorer overall survival (OS) as compared to medium and low BRD4 expression (P ¼ 0.0003). JQ1 reduced cell growth in vivo and in vitro by inducing G0/G1 cell cycle arrest and apoptosis in SU-R-786-o cells more than in the parent cells (P < 0.01). Also, JQ1 suppressed MYC expression in SU-R-786-o cells (P < 0.0001). RNA sequence analysis revealed that several oncogenes were significantly downregulated in JQ1 treated-SU-R-786-o. Among those genes, we found that SCG5, SPOCD1, RGS19, and ARHGAP22 were novel independent predictors for OS in RCC by analyzing TCGA database (P ¼ 0.0425, P ¼ 0.0003, P ¼ 0.0013, and P ¼ 0.0179, respectively).
CONCLUSIONS: BRD4 inhibition could be a potential therapeutic approach in sunitinib-resistant RCC. We also found that MYC, known target of JQ1, as well as, novel independent predictors of RCC such as SCG5, SPOCD1, RGS19, and ARHGAP22 were suppressed by JQ1. The discovery of molecular targets regulated by BRD4 could provide important insights into potential mechanisms of sunitinib resistance in RCC.
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MP72-05 IL-6-TRIGGERED POSITIVE FEEDBACK LOOP FOR NFkB SIGNALING INDUCES TKI RESISTANCE THROUGH METABOLIC ALTERATIONS ON RENAL CELL CARCINOMA CELLS
Kei Ishibashi*, Akihumi Onagi, Ryo Tanji, Ruriko Takinami, Kanako Matsuoka, Tomoyuki Koguchi, Seiji Hoshi, Junya Hata, Yuichi Sato, Hidenori Akaihata, Masao Kataoka, Soichiro Ogawa, Nobihuro Haga, Ken Aikawa, Yoshiyuki Kojima, Fukushima, Japan INTRODUCTION AND OBJECTIVES: Tyrosine-kinase inhibitors (TKI) treatment targeted at the VEGF pathways represents the standard of care in advanced renal cell carcinoma (RCC). Although the TKI treatment has promising effect against RCC, the development of resistance to TKIs should be solved. We show that the autocrine secretion of IL-6 induced by TKIs-stimulation causes metabolic alterations which leads TKI resistance through Inflammation amplifier.
METHODS: Human renal cell carcinoma cell line 786-O and sunitinib were used for this study. GLUT1 expression and IL-6 secretions from 786-O cells cultured with TKIs were measured by real-time PCR and ELISA. Western blot analyses were applied for detection of GLUT1 as well as LAT1 and ASCT2 proteins. ChIP analysis of the IL-6 promotor region were performed using antibody against NFkB. Metabolic alterations in RCC cells treated by TKI were evaluated by CE-TOFMS analysis. The growth of tumors and GLUT1 expression in athymic mice receiving combination therapy with IL-6R antibody and sunitinib were evaluated by FDG-PET and immunohistochemical examinations.
RESULTS: The 786-O RCC cell line secreted IL-6 when they were cultured with sunitinib. Western blot analysis revealed that Akt and mTOR were phosphorylated by sunitinib stimulation. Tocilizumab treatment in combination with sunitinib reduced activation of IL-6 signaling pathway and also suppressed cell proliferation and GLUT1 expression. ChiP assay showed that the peak of NFkB binding was obtained by real time PCR amplifying the region located from -721 to -621 on the 50-flanking region. CE-TOFMS analysis revealed the increase of glucose-6-phosphate and fructose 6-phosphate by sunitinib treatment which lead to glycolysis. High ATP and NADH were also observed by TKI stimulation. Level of these metabolites were reduced by use of IL-6R antibody. Combination treatment withIL-6R antibody Vol. 199, No. 4S, Supplement, Sunday, May 20, 2018 THE JOURNAL OF UROLOGY â e953
